SCHEMBL308657

SCHEMBL308657

Cc1ccc2c(=O)n(C3CCN(C(=O)OC(C)(C)C)C3)ccc2c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.44
EGFR P00533 3/20 0.44
PIK3CA P42336 1/20 0.43
CTSD P07339 1/20 0.42
CTSE P14091 1/20 0.42
BACE1 P56817 1/20 0.42
USP30 Q70CQ3 2/20 0.42
ABL1 P00519 2/20 0.42
ABL2 P42684 2/20 0.42
TP53 P04637 1/20 0.39
GPR119 Q8TDV5 3/20 0.39
HCAR1 Q9BXC0 1/20 0.38
PRKCG P05129 1/20 0.37
PRKCB P05771 1/20 0.37
PRKCA P17252 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCD Q05655 1/20 0.37
MDM2 Q00987 1/20 0.37
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL308658 1.00 SRC (0.44) SRCEGFRPIK3CACTSDCTSE
SCHEMBL306712 0.84 SRC (0.39) SRCEGFRPIK3CACTSDCTSE
SCHEMBL306711 0.84 SRC (0.39) SRCEGFRPIK3CACTSDCTSE
SCHEMBL19513997 0.80 KDM5A (0.52) SRCEGFRPIK3CAUSP30ABL1
SCHEMBL4385936 0.78 PRKCG (0.47) CTSDCTSEBACE1USP30TP53
SCHEMBL25150818 0.77 USP30 (0.44) SRCEGFRPIK3CAUSP30ABL1
SCHEMBL30398886 0.77 USP30 (0.44) SRCEGFRPIK3CAUSP30ABL1
SCHEMBL25151430 0.77 SRC (0.44) SRCEGFRPIK3CAUSP30ABL1
SCHEMBL14824043 0.75 GPR119 (0.51) SRCEGFRPIK3CAUSP30ABL1
SCHEMBL19513984 0.75 SRC (0.49) SRCEGFRUSP30ABL1ABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2124562-B1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF SECOND GENOME INC (US) 2016-04-20 EP disclosed
US-8093265-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof RENOVIS, INC. (US) 2012-01-10 US disclosed
EP-2124562-A1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF Renovis, Inc. (US) 2009-12-02 EP disclosed
US-20080287415-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof SECOND GENOME, INC. 2008-11-20 US disclosed
WO-2008112205-A1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287415-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof P2RX7, P2RX3, P2RX2 SRC 2112/4885EGFR 4690/4885PIK3CA 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.